CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Multityrosinkinase inhibition by sorafenib increases necrosis size after radiofrequency ablation in rat liver through antiangiogenesis but activates compensatory growth signalling
DOI 10.1055/s-0029-1246430
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJC Mertens, IV Martin, J Schmitt, P Frei, AH Mahnken, B Müllhaupt, A Geier
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: The most widely employed local treatment for unresectable HCC is radiofrequency ablation (RFA). The multityrosinkinase inhibitor sorafenib (S) has shown survival benefits in pts at advanced stages and is under investigation for adjuvant treatment after HCC resection/ablation in human trials. Of potential concern, S may reduce liver regeneration after tissue ablation. Aim: To evaluate effects of combined sorafe…
Zitieren
Zitierempfehlung
JC Mertens, IV Martin, J Schmitt, P Frei, AH Mahnken, B Müllhaupt, A Geier (2010) Multityrosinkinase inhibition by sorafenib increases necrosis size after radiofrequency ablation in rat liver through antiangiogenesis but activates compensatory growth signalling. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0029-1246430
Mit CareLit weiterarbeiten